Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
Regorafenib had no impact on overall survival in a placebo-controlled trial in 199 patients, but adverse effects were frequent and serious. Symptomatic care is a more reasonable choice.